FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileNeurizon Therapeutics Limited
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
NUZ.AX
Neurizon Therapeutics Limited Stock AnalysisComprehensive stock analysis for Neurizon Therapeutics Limited (NUZ.AX) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisNUZ.AX
NUZ.AX
Neurizon Therapeutics Limited
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
NUZ.AX
  1. Home
  2. Stocks
  3. Neurizon Therapeutics Limited

Neurizon Therapeutics Limited

🇦🇺NUZ.AX•ASX

Neurizon Therapeutics Limited

🇦🇺NUZ.AX•ASX

Your view on NUZ.AX

Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Neurizon Therapeutics Limited

Industry
Biotechnology
Sector
Healthcare
CEO
Ben Dingle
Headquarters
Suite 2, Melbourne, VIC, AU
Industry
Biotechnology
Sector
Healthcare
CEO
Ben Dingle
Headquarters
Suite 2, Melbourne, VIC, AU
Description

Neurizon Therapeutics Limited, a clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases. The company develops drug discovery intellectual property for the treatment of neurological diseases.

Its lead candidate is NUZ-001, a small molecule drug which is in Phase II clinical trials for the treatment of amyotrophic lateral sclerosis, as well as to treat other neurodegenerative diseases. The company was formerly known as PharmAust Limited and changed its name to Neurizon Therapeutics Limited in October 2024.

Neurizon Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Neurizon Therapeutics Limited. Starting points for Neurizon Therapeutics Limited: EPS -AUD 0.01, beta 1.31 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Neurizon Therapeutics Limited. Neurizon Therapeutics Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Neurizon Therapeutics Limited. Trailing twelve-month EPS for Neurizon Therapeutics Limited stands at -AUD 0.01. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Neurizon Therapeutics Limited. Neurizon Therapeutics Limited has reported as a listed company since 2001. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold NUZ.AX12 companies
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
ONCYOncolytics Biotech Inc.HealthcareNASDAQ$35.1M
ONPHOncology Pharma Inc.HealthcareOTC$109,553
ONTTFOxford Nanopore Technologies plcHealthcareOTC$1.8B
OPORFhVIVO plcHealthcareOTC$59.2M
ORGSOrgenesis Inc.HealthcareOTC$3.0M
ORICORIC Pharmaceuticals, Inc.HealthcareNASDAQ$764.9M
ORKAOruka Therapeutics, Inc.HealthcareNASDAQ$6.5B
ORMPOramed Pharmaceuticals Inc.HealthcareNASDAQ$155.2M
ORPOFOSE Immunotherapeutics S.A.HealthcareOTC$260.3M
ORYZFOryzon Genomics S.A.HealthcareOTC$283.9M
OSRHWOSR Holdings, Inc.HealthcareNASDAQ$7.8M
OSTXOS Therapies IncorporatedHealthcareAMEX$42.0M
Ownership & News

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Neurizon Therapeutics Limited. Coverage tracks Neurizon Therapeutics Limited within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Neurizon Therapeutics Limited.

NUZ.AX AnalysisFair
Past
1
Growth
5
Health
4
Profit
1
Value
1